Short- and long-term risk stratification using a next-generation, high-sensitivity research cardiac troponin I (hs-cTnI) assay in an emergency department chest pain population.
BACKGROUND
The next-generation, high-sensitivity cardiac troponin assays can measure quantifiable concentrations of cTn in a majority of individuals, but there are few studies assessing these assays for risk stratification. The present study was undertaken to determine if a research hs-cTnI assay can be useful for predicting death/myocardial infarction (MI), both short- and long-term, in an emergency department acute coronary syndrome (ACS) population.


METHODS
In a cohort of 383 subjects, originally recruited in 1996, presenting to the emergency department with symptoms suggestive of ACS, the heparin plasma obtained at initial presentation was thawed and measured in 2007 with a research hs-cTnI assay. AccuTnI (Beckman Coulter) measurements were made on these same samples in 2003. The population was divided into 4 groups by hs-cTnI: <5.00, 5.00-9.99, 10.00-40.00, and >40.00 ng/L. Kaplan-Meier, Cox proportional hazards, ROC curves, and logistic regression analyses were used to identify which hs-cTnI concentrations were predictive of death/MI within 10 years after presentation.


RESULTS
There were significant differences between the hs-cTnI groups for the probability of death/MI up to 10 years after presentation (P < 0.05). At 6 months, patients with hs-cTnI > or =10.00 ng/L were at higher risk for death/MI (hazard ratio >3.7; P < 0.05) compared with those having hs-cTnI <5.00 ng/L. ROC curve analysis for death/MI at 30 days with the hs-cTnI assay had an area under the curve of 0.74 (95% CI 0.65-0.82), with logistic models yielding an optimal assay threshold of 12.68 ng/L.


CONCLUSIONS
This research hs-cTnI assay appears useful for risk stratification for death/MI in an ACS population.
Kavsak
Peter A
PA
Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada. kavsakp@mcmaster.ca
Wang
Xuesong
X
Ko
Dennis T
DT
MacRae
Andrew R
AR
Jaffe
Allan S
AS
D054058:Acute Coronary Syndrome / Q000097:blood / Q000175:diagnosis* / Q000401:mortality; D000368:Aged; D015415:Biomarkers / Q000097:blood; D002637:Chest Pain / Q000097:blood / Q000175:diagnosis* / Q000401:mortality; D004636:Emergency Service, Hospital; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood / Q000175:diagnosis*; D011237:Predictive Value of Tests; D011336:Probability; D012372:ROC Curve; D018570:Risk Assessment; D013997:Time Factors; D019210:Troponin I / Q000097:blood*
D015415:Biomarkers; D019210:Troponin I
Clin Chem. 2009 Jan;55(1):5-8
19028812
Clin Chem. 2009 Jan;55(1):52-8
18988755
Clin Chem. 2009 May;55(5):930-7
19299542
Am Heart J. 2002 Aug;144(2):290-6
12177647
Clin Chem. 2006 Nov;52(11):2157-9
18061987
Clin Chem. 2009 Jan;55(1):85-92
18988758
Am Heart J. 2006 Jul;152(1):118-25
16824840
Circulation. 2007 Sep 11;116(11):1242-9
17698733
Clin Chem. 2009 Jan;55(1):15-7
19028819
Clin Chem. 2007 Aug;53(8):1558-60
17644798
Am Heart J. 2008 Feb;155(2):208-14
18215588
Clin Chem. 2001 May;47(5):959-61
11325911
Clin Chem. 2009 Mar;55(3):573-7
19168557
Clin Chem. 2008 Jul;54(7):1234-8
18593962
Circulation. 2006 Feb 28;113(8):1071-8
16490824
Clin Chem. 2009 Jan;55(1):101-8
18988757
J Am Coll Cardiol. 2007 Nov 27;50(22):2173-95
18036459
J Am Coll Cardiol. 2006 Nov 7;48(9):1763-4
17084246
Clin Chem. 2007 Feb;53(2):220-7
17204519
Circulation. 2007 Oct 23;116(17):1907-14
17909103